Cancer vaccine composition

Patent metadata

Field	Value
Publication number	US-10426822-B2
Application number	US-201615530247-A
Country	US
Kind code	B2
Filing date	Dec 16, 2016
Priority date	Dec 5, 2007
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.

First claim

The invention claimed is:

1. A method of cancer treatment, comprising administering to an HLA-A*0206-positive person a composition comprising at least one of a modified peptide of the WT1 187 peptide: Ser Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 2) or a modified peptide of the WT1 126 peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), wherein the modified peptide is a peptide comprising the amino acid residues at position 4 to 8 from the N terminus of the WT1 187 or WT1 126 peptide and is immunogenic in HLA-A*0206-positive persons.

2. The method of claim 1 , wherein the composition comprises the modified peptide of the WT1 187 peptide.

3. The method of claim 1 , wherein the composition comprises the modified peptide of the WT1 126 peptide.

4. The method of claim 1 , wherein the modified peptide has the amino acid sequence of SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 17, 18, 19, 21, 22, 23, 24, 25 or 26.

5. The method of claim 1 , wherein the modified peptide has the amino acid sequence of SEQ ID NO: 54, 55, 56, 57, 58, 59, 60, 61 or 62.

6. The method of claim 1 , wherein the modified peptide has the amino acid sequence of SEQ ID NO: 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 47, 48, 50, 51 or 52.

7. The method of claim 1 , wherein the modified peptide has the amino acid sequence of SEQ ID NO: 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75.

8. The method of claim 1 , wherein the HLA-A*0206-positive person has leukemia.

9. The method of claim 1 , wherein the composition is administered orally or parenterally.

10. The method of claim 1 , wherein the composition is administered at a daily dose of 0.0001 mg to 1000 mg.

11. The method of claim 1 , wherein the composition is administered at a daily dose of 0.01 mg to 1000 mg.

12. The method of claim 1 , wherein the composition is administered at a daily dose of 0.1 mg to 10 mg.

13. The method of claim 1 , wherein the HLA-A*0206-positive person has a cancer accompanied by increased expression of the WT1 gene.

14. The method of claim 1 , wherein the HLA-A*0206-positive person has a hematopoietic tumor.

15. The method of claim 1 , wherein the HLA-A*0206-positive person has myelodysplastic syndrome, multiple myeloma and/or malignant lymphoma.

16. The method of claim 1 , wherein the HLA-A*0206-positive person has a solid cancer.

17. The method of claim 1 , wherein the HLA-A*0206-positive person has at least one of gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.

Assignees

• Int Inst Cancer Immunology Inc

Inventors

• Sugiyama Haruo

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• G01N33/57595

  involving intracellular compounds · CPC title